跳至主要内容
临床试验/NCT05613764
NCT05613764已完成不适用

Message From Local Pharmacy Team

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 520,000 人开始时间: 2022年11月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
520,000
试验地点
2
主要终点
Patient uptake of COVID bivalent booster

研究概览

简要总结

This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a control message telling patients that an updated COVID booster vaccine is waiting for them. The intervention testing if text messages encouraging vaccination that come from a patient's local pharmacy team will produce more vaccinations than otherwise identical messages.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Care Provider, Outcomes Assessor)

盲法说明

As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message
  • The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

结局指标

主要结局

Patient uptake of COVID bivalent booster

时间窗: During the 30 days after receiving the SMS/MMS intervention

Whether patients receive a bivalent COVID booster at the pharmacy in question

次要结局

  • Patient uptake of COVID bivalent booster(90 days after receiving the SMS/MMS intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Message Communicating Latest Data on COVID-19 Transmission in Patient's AreaCOVID-19
NCT05621226University of Pennsylvania520,000
已完成
不适用
Planning Message Recommending Same Time/Location as Last VaccineCOVID-19
NCT05612386University of Pennsylvania520,000
已完成
不适用
Message Offering Free Round Trip Ride-Share Ride to PharmacyCOVID-19
NCT05612373University of Pennsylvania300,000
进行中(未招募)
1 期
Ensayo clínico mundial, abierto, para analizar la seguridad y tolerabilidad a largo plazo de rizatriptán en el tratamiento de la migraña, con o sin aura, de niños migrañosos. // A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura.
EUCTR2009-016375-30-ESMerck & Co., Inc.606
进行中(未招募)
1 期
A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART).Ensayo exploratorio farmacogenómico, multinacional y multicéntrico, para examinar la importancia de los marcadores genéticos identificados y, potencialmente, identificar nuevos marcadores de diversas respuestas ováricas al tratamiento con GONAL f® en mujeres sometidas a técnicas de reproducción asistida (ART) - Pharmacogenomics trial of GONAL-f® in ARTFemales undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)Mujeres sometidas a ténicas de reproducción asistida (ART), fertilización in vitro (IVF) o inyección intracitoplásmica de espermatozoides (ICSI)MedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOS
EUCTR2008-001174-33-ESMerck Serono International, A branch of Laboratoires Serono S.A.